What is CODAGENIX?
Codagenix operates at the intersection of synthetic biology and immunology, specializing in the design of precise edits into viral genomes. The company's core platform is engineered to produce live-attenuated vaccines that offer the robust immunity associated with traditional live-attenuated viruses while significantly enhancing safety and manufacturing scalability. This technological edge allows Codagenix to address infectious disease threats that have historically proven difficult to manage with conventional vaccine methodologies.
By focusing on high-burden public health challenges, the company has established itself as a transformative player in the life sciences landscape. Its market position is bolstered by a history of strategic partnerships and non-dilutive funding, which have enabled the firm to transition from early-stage research to advanced clinical development. The company's commitment to innovation and global health impact remains the cornerstone of its operational strategy.
How much funding has CODAGENIX raised?
CODAGENIX has raised a total of $49M across 5 funding rounds:
Multiple Rounds
$2M
Series A
$2M
Series B
$45M
Unspecified (2014): $100K with participation from Accelerate Long Island
Grant (2014): $222K led by National Institutes of Health
Angel/Seed (2014): $1.7M supported by National Institutes of Health and State of New York - Empire State Development
Series A (2015): $2M featuring Topspin Partners
Series B (2023): $45M backed by Serum Institute of India Pvt. Ltd., Euclidean Capital, and Adjuvant Capital
Key Investors in CODAGENIX
Adjuvant Capital
Adjuvant Capital is a venture capital firm focused on financing innovative life science technologies that address high-burden public health challenges, particularly in infectious diseases and maternal health.
Serum Institute of India Pvt. Ltd.
Founded in 1966, the Serum Institute of India is a global leader in the manufacturing of immunobiological drugs and vaccines, providing critical industrial expertise and scale.
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing foundational support for scientific innovation.
What's next for CODAGENIX?
Looking ahead, the recent capital injection is expected to catalyze the next phase of Codagenix's growth, focusing on the clinical validation of its lead candidates and the expansion of its therapeutic platform. The company is likely to prioritize the scaling of its manufacturing capabilities to meet global demand, while simultaneously exploring new applications for its synthetic biology engine. As the firm moves deeper into its lifecycle, the focus will shift toward regulatory milestones and the commercialization of its vaccine portfolio. By maintaining its commitment to rigorous scientific standards and strategic collaboration, Codagenix is poised to remain a leader in the development of next-generation medical countermeasures against emerging infectious diseases.
See full CODAGENIX company page
